eosinophilic oesophagitis
Gastroenterology · 2015–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| budesonide Treatment of eosinophilic oesophagitis (EoE) in adults. The submission requested changes to PBS listings including removal of the requirement for histological… | Jul 2023 | Deferred | input received Australasian Society of Clinical Immunology and Allergy · Anaphylaxis Australia |
| budesonide Treatment of eosinophilic oesophagitis (EoE) in adults, both for induction of remission and maintenance of remission. | Mar 2021 | Not recommended | input received |
| budesonide Treatment of eosinophilic oesophagitis (EoE) in adults, for both induction of remission and maintenance of remission. | Nov 2021 | Recommended with restriction | 7 individuals Australasian Society of Clinical Immunology and Allergy |
| amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides Eosinophilic oesophagitis and severe intestinal malabsorption including short bowel syndrome (Alfamino®); eosinophilic oesophagitis (Alfamino® Junior). | Nov 2015 | Recommended with restriction | none received |
Who spoke
Australasian Society of Clinical Immunology and Allergy · Anaphylaxis Australia
What the PBS pays
$111M in government benefit over 2024–25, across 2,698,651 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| budesonide | $102.1M |
| amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides | $9.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| dupilumabDupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | terminated | 2023-12 |
| budesonide orodispersible tabletBudesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | recommended | 2021-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.